Resistance to targeted therapy in leukaemia
- 1 February 2002
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 359 (9305) , 458-459
- https://doi.org/10.1016/s0140-6736(02)07671-7
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- All trans retinoic acid in acute promyelocytic leukemiaOncogene, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patientsDrug Resistance Updates, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000